BioMarin Pharmaceutical Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BMRN | BBIO | 1952.HK | 0NZU.IL | IONS | KRYS | |
|---|---|---|---|---|---|---|
| Market cap | 11.06B | 15.17B | 9.83B | 14.45B | 6.67B | 9.21B |
| P/E (TTM) | — | — | — | — | — | 42.2 |
| Forward P/E | 9.0 | -225.0 | 20.4 | — | -35.0 | 34.0 |
| Price/book | 1.8 | -5.9 | 1.3 | 8.2 | 15.1 | 6.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +10.20% | +24.17% | −44.53% | −43.38% | −45.82% | +55.44% |
| Today | +2.64% | +5.21% | +5.06% | +1.66% | −0.67% | +1.90% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All BMRN news ›BioMarin Pharmaceutical Inc. 2026 Q3 - Results - Earnings Call Presentation
2026-11-05. The following slide deck was published by BioMarin Pharmaceutical Inc. The following slide deck was published by BioMarin Pharmaceutical Inc. in conjunction with their 2026 Q3 earnings call. Q3: 2026-11-02 Earnings Summary
BioMarin: Better Risk-Reward Ahead Of Three FDA Decisions
BioMarin is a speculative Buy as lower valuation, FDA catalysts, and Voxzogo growth potential may reward long-term investors. Click to read more on BMRN stock. - BioMarin’s lower valuation and broader commercial portfolio now offer a…
Biocon Q2 Profit Falls 52% YoY 41 Crore; Co. Secures USD 400 Million Brazil Biosimilar Deal
Biocon’s consolidated operating revenue rose 2 per cent year-on-year to Rs 4,389 crore during the quarter. The company’s biopharma revenue grew 5 per cent to Rs 3,583 crore. Within the segment, biosimilars revenue increased 3 per cent…
Cellectar Biosciences (CLRB) Set to Release Quarterly Earnings on Tuesday
Posted by Sarita Garza on Nov 4th, 2026 Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.57) EPS for the quarter,…
BioMérieux Reports 10 Percent Q3 Sales Growth
BioMérieux Q3 Sales up 10 Percent, Lifted by Non-Respiratory MDx Tests GenomeWeb BioMérieux Q3 Sales up 10 Percent, Lifted by Non-Respiratory MDx Tests
BioMarin to Participate in Upcoming Investor Conferences
PR Newswire - Stifel Healthcare Conference, November 11 at 3:20 pm EST - UBS Global Biopharma Conference, November 16 at 9:20 am GMT - Jefferies Global Healthcare Conference, November 17 at 11:30 am GMT SAN RAFAEL, Calif., Nov. 4, 2026 /PRN
BioMarin Pharmaceutical Inc. Stock 12‑Month Price Target Cut to $90.85, Implies 58% Upside
TradingView BioMarin Pharmaceutical Inc. Stock 12‑Month Price Target Cut to $90.85, Implies 58% Upside - According to estimates from 26 analysts, BioMarin Pharmaceutical Inc. stock's average price target has
BioMarin anticipates $3.8B-$3.9B 2026 revenue while flagging $70M order deferrals
BioMarin Q3 2026 earnings: revenue topped $1B, guidance was updated on order delays, and pipeline momentum continued. Earnings Call Insights: BioMarin Pharmaceutical Inc. (BMRN) Q3 2026 "Strong demand across our diversified portfolio of…
Robert W. Baird Reaffirms Their Hold Rating on BioMarin Pharmaceutical (BMRN)
In a report released yesterday, Jack Allen from Robert W. Baird maintained a Hold rating on BioMarin Pharmaceutical, with a price target of $65.00. The company’s shares closed yesterday at $55.35. According to TipRanks, Allen is an analyst…
Biogen Pharmachem Industries reports profit of ₹25.73 crore for Q2 2026
Biogen Pharmachem reports ₹25.73 lakh Q2 profit InvestyWise Biogen Pharmachem Industries reports profit of ₹25.73 crore for Q2 2026 Biogen Pharmachem Industries Limited has announced its unaudited financial results for the quarter and…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com11
- seekingalpha.com9
- prnewswire.com5
- marketscreener.com4
- theglobeandmail.com3
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 52 articles, not a forecast.